{"type":"trials","record":{"id":22016,"source_id":"clinicaltrials-gov","external_id":"NCT05975528","title":"Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Type 2 Diabetes","brief_summary":"Patients with type 2 diabetes (T2D) are more prevalent with aging-related comorbidities and frailty, which leads to a shorter life expectancy than non-diabetic individuals and that this excess mortality is largely attributable to cardiovascular causes. Therefore, since diabetes accelerates cellular senescence, attenuating aging process in patients with T2D is expected to reduce progression of comorbidities and eventually increase lifespan. According to previous studies, sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown increased ketone bodies not only in blood but in various tissues including liver, kidney and colon, which could lead to beneficial effects in metabolic diseases. Especially, β-hydroxybutyrate (βHB) inhibits oxidative stress and reduces insulin resistance, which has a positive effect on preventing cardio-renal-metabolic diseases and aging process in patients with T2D. In this context, SGLT2 inhibitor can be a promising option to alleviate senescence process in patients with T2D. However, despite the accumulating evidence that support anti-senescent effect of SGLT2 inhibitor in preclinical models, no clinical study has investigated association between SGLT2 inhibitor use and senescence patients with T2D. Thus, the objective of this study is to determine whether the use of SGLT2 inhibitor is associated with anti-senescent effect in patients with T2D, which may expand the indications of SGLT2 inhibitor other than glycemic control.","overall_status":"Unknown","phases":["PHASE4"],"study_type":"INTERVENTIONAL","sponsor":"Yonsei University","enrollment":92,"countries":["South Korea"],"start_date":"2023-06-01","completion_date":"2025-12-31","last_update_date":"2024-05-09","source_url":"https://clinicaltrials.gov/study/NCT05975528","editorial_summary":"A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-24T01:17:14.135638+00:00","last_seen_at":"2026-09-25T06:20:04.694+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years to 85 Years","comparator":"Glimepiride user","organization":"Yonsei University","interventions":["SGLT2 inhibitor","Glimepiride"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Changes of Cellular senescence markers — Changes from baseline to 3 months after use of SGLT2 inhibitors","Changes of Senescence-associated secretory phenotype — Changes from baseline to 3 months/6 months after use of SGLT2 in…","Changes of biochemistry profiles in blood (10^3/μL) — Changes from baseline to 3 months/6 months after use of SGLT2 inh…","Changes of biochemistry profiles in blood (g/dL) — Changes from baseline to 3 months/6 months after use of SGLT2 inhibi…","Changes of biochemistry profiles in blood (%) — Changes from baseline to 3 months/6 months after use of SGLT2 inhibitors","Changes of biochemistry profiles in blood (mg/dL) — Changes from baseline to 3 months/6 months after use of SGLT2 inhib…","Changes of biochemistry profiles in blood (IU/L) — Changes from baseline to 3 months/6 months after use of SGLT2 inhibi…","Changes of biochemistry profiles in blood (mg/L) — Changes from baseline to 3 months/6 months after use of SGLT2 inhibi…","Changes of biochemistry profiles in blood (μEq/L) — Changes from baseline to 3 months/6 months after use of SGLT2 inhib…","Changes of biochemistry profiles in blood (μU/mL) — Changes from baseline to 3 months/6 months after use of SGLT2 inhib…","Changes of biochemistry profiles in blood (mmol/L) — Changes from baseline to 3 months/6 months after use of SGLT2 inhi…","Changes of body composition using Inbody (kg) — Changes from baseline to 3 months/6 months after use of SGLT2 inhibitors","Changes of body composition using Inbody (cm) — Changes from baseline to 3 months/6 months after use of SGLT2 inhibitors","Changes of body composition using Inbody (cm2) — Changes from baseline to 3 months/6 months after use of SGLT2 inhibito…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":false},"controlled_terms":["Diabetes Mellitus","Cellular Senescence","Sodium-Glucose Transporter 2 Inhibitors","SGLT2 inhibitor","Glimepiride"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: cellular senescence.","quality_checked_at":"2026-09-25T06:20:05.499352+00:00","duplicate_cluster_key":"id:nct05975528","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-06-01 to 2025-12-31","comparator":"Glimepiride user","confidence":"structured-source","population":"ALL · 50 Years to 85 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:04.705Z","intervention":["SGLT2 inhibitor","Glimepiride"],"participants":92,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE4","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Changes of Cellular senescence markers — Changes from baseline to 3 months after use of SGLT2 inhibitors","Changes of Senescence-associated secretory phenotype — Changes from baseline to 3 months/6 months after use of SGLT2 in…","Changes of biochemistry profiles in blood (10^3/μL) — Changes from baseline to 3 months/6 months after use of SGLT2 inh…","Changes of biochemistry profiles in blood (g/dL) — Changes from baseline to 3 months/6 months after use of SGLT2 inhibi…","Changes of biochemistry profiles in blood (%) — Changes from baseline to 3 months/6 months after use of SGLT2 inhibitors","Changes of biochemistry profiles in blood (mg/dL) — Changes from baseline to 3 months/6 months after use of SGLT2 inhib…","Changes of biochemistry profiles in blood (IU/L) — Changes from baseline to 3 months/6 months after use of SGLT2 inhibi…","Changes of biochemistry profiles in blood (mg/L) — Changes from baseline to 3 months/6 months after use of SGLT2 inhibi…","Changes of biochemistry profiles in blood (μEq/L) — Changes from baseline to 3 months/6 months after use of SGLT2 inhib…","Changes of biochemistry profiles in blood (μU/mL) — Changes from baseline to 3 months/6 months after use of SGLT2 inhib…","Changes of biochemistry profiles in blood (mmol/L) — Changes from baseline to 3 months/6 months after use of SGLT2 inhi…","Changes of body composition using Inbody (kg) — Changes from baseline to 3 months/6 months after use of SGLT2 inhibitors","Changes of body composition using Inbody (cm) — Changes from baseline to 3 months/6 months after use of SGLT2 inhibitors","Changes of body composition using Inbody (cm2) — Changes from baseline to 3 months/6 months after use of SGLT2 inhibito…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"senolytics","is_published":true,"match_reasons":["Title contains controlled term: cellular senescence.","Abstract contains controlled term: cellular senescence.","Source terminology contains: cellular senescence.","Title supplies longevity context: senescence.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Senolytics","slug":"senolytics"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/22016","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}